Randomised controlled trials of tofacitinib in rheumatoid arthritis
| Study | N | Population | Disease duration (years) | Background treatment | Comparator | Trial duration |
|---|---|---|---|---|---|---|
| Kremer, 200928 | 264 | DMARD-IR | 9.5 | DMARDs | Placebo | 6 Weeks |
| Tanaka, 201129 | 140 | MTX-IR | 8.3 | MTX | Placebo | 12 Weeks |
| Kremer, 201230 | 507 | MTX-IR | 9.5 | MTX | Placebo | 24 Weeks |
| Fleischmann, 201231 | 384 | DMARD-IR | 9.0 | None | Placebo | 24 Weeks |
| ORAL Scan | ||||||
| Van der Heijde, 201332 | 797 | MTX-IR | 9.0 | MTX | Placebo | 24 Months |
| ORAL Sync Kremer, 2011*33 | 792 | DMARDs-IR | 9.1 | Non biological DMARDs | Placebo | 12 Months |
| ORAL Standard | ||||||
| Van Vollenhoven, 201234 | 717 | MTX-IR | 7.5 | MTX | Placebo | 12 Months |
| ORAL Step” Burmester, 201335 | 399 | TNFi-IR | 12.0 | MTX | Placebo | 6 Months |
| ORAL Solo” Fleischmann, 201236 | 611 | DMARDs-IR | 8.2 | None | Placebo | 6 Months |
| ORAL Start* Lee, 201237 | 952 | MTX naïve | NA | None | MTX | 24 Months |
All trials were randomised controlled trials with a low ‘risk of bias’ score.
*This study was reported in abstract form only.
DMARDs, disease-modifying antirheumatic drugs; IR, inadequate responder; MTX, methotrexate; NA, not available; TNFi, tumour necrosis factor inhibitor.